SCHEMBL5928910

SCHEMBL5928910

CCCCn1c(-c2ccccc2C)nc(Cl)c1CN1CCCCC1C(=O)OCC

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.47
▸ TSHR P16473 3/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ RECQL P46063 1/20 0.47
▸ ALDH1A1 P00352 5/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ POLB P06746 2/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ KCNH2 Q12809 1/20 0.43
▸ CD274 Q9NZQ7 4/20 0.39
▸ PDCD1 Q15116 2/20 0.39
▸ KCNK3 O14649 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ MAPT P10636 1/20 0.37
▸ GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5929161 0.82 CYP3A4 (0.36) KDM4ETSHRMAPK1ALDH1A1MEN1
SCHEMBL5929150 0.80 KDM4E (0.50) KDM4ETSHRMAPK1RECQLALDH1A1
SCHEMBL5929361 0.79 KDM4E (0.43) KDM4ETSHRALDH1A1MEN1KMT2A
SCHEMBL5929011 0.79 KMT2A (0.38) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL5928957 0.78 MEN1 (0.44) KDM4EALDH1A1MEN1KMT2ACYP2D6
SCHEMBL5929232 0.77 PARP1 (0.40) KDM4EALDH1A1MEN1KMT2ACYP3A4
SCHEMBL5929191 0.77 KDM4E (0.52) KDM4ETSHRMAPK1RECQLALDH1A1
SCHEMBL5929140 0.77 SMN1; SMN2 (0.38) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL5929026 0.77 KDM4E (0.38) KDM4ETSHRALDH1A1MEN1KMT2A
SCHEMBL5928918 0.77 KDM4E (0.46) KDM4EALDH1A1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060154917-A1 Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators NEUROGEN CORPORATION (US) 2006-07-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154917-A1 Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators C5AR1, C5AR2, C3AR1 KDM4E 1762/4885TSHR 472/4885MAPK1 1079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback